Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis

Research output: Contribution to journalReview article

11 Scopus citations

Abstract

In this article, an overview of lessons from cost-effectiveness analyses of disease-modifying drugs for the treatment of multiple sclerosis is provided. Special attention is paid to the uncertainty in reaching a conclusion from the economic evaluations. If recent debates over multiple sclerosis drugs are any indication, the public's understanding of why one conducts an economic evaluation may be at least as important as the cost-effectiveness estimate from the analysis.

Original languageEnglish (US)
Pages (from-to)537-547
Number of pages11
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume4
Issue number5
DOIs
StatePublished - Oct 2004
Externally publishedYes

Keywords

  • Cost utility
  • Cost-effectiveness
  • Multiple sclerosis
  • Rationing

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'Cost-effectiveness lessons from disease-modifying drugs in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

  • Cite this